Showing 2901-2910 of 10054 results for "".
DermwireTV: Deucravacitinib Maintains Efficacy in PsO at 3 Years
https://practicaldermatology.com/programs/practical-dermatology/dermwiretv-deucravacitinib-maintains-efficacy-in-pso-at-3-years/37249/In this episode of DermwireTV, deucravacitinib maintains efficacy for plaque psoriasis through 3 years in a new analysis; GLP-1 medications may be fueling a rise in aesthetic procedures, according to new research; and Drs. Tina Bhutani and Lisa Swanson weigh in on transitioning from academia to privDermwireTV: DermaRite Issues Recall for Several Hand Soaps
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-dermarite-issues-recall-for-several-hand-soaps/37113/In this episode, new research shows switching between interclass biologics may be safe and effective for psoriasis patients; DermaRite recalls 4 skin care products over contamination concerns; and awareness grows for generalized pustular psoriasis through a new global awareness campaign.FDA Grants Interchangeability to HADLIMA
https://practicaldermatology.com/series/dermwire-tv/fda-grants-interchangeability-to-hadlima/35962/In this week's DermwireTV, the FDA grants full interchangeability to HADLIMA; new research shows the impact of UV exposure on global skin cancer cases; and coverage from Music City SCALE addresses barriers to patient access to new therapies.Nail Disease and JAK Inhibitor Safety
https://practicaldermatology.com/programs/practical-dermatology/nail-disease-and-jak-inhibitor-safety/35897/Brad Glick, DO, talks about the basics of nail anatomy, physiology, disease presentation, and treatments, as well as the safety of JAK inhibitors, at Music City SCALE 2025.Study Examines Socioeconomic Status and HS Diagnosis
https://practicaldermatology.com/series/dermwire-tv/study-examines-socioeconomic-status-and-hs-diagnosis/35859/In this week's DermwireTV, a new study examines the association between socioeconomic status and HS diagnosis; a new meta-analysis highlights the therapeutic potential of simvastatin for vitiligo; and in our “Updates on Skin Cancer” feature, we hear about how to use gene expression profile testing fSunscreen as Self-Care
https://practicaldermatology.com/series/c-suite-chats/sunscreen-as-self-care/33249/Arielle Moody, product developer at Mama Sol, talks about the importance of sunscreen in beauty routines and how her company is attempting to make it more appealing.Leading Dermatologists Summarize Maui Derm Presentations
https://practicaldermatology.com/series/dermwire-tv/leading-dermatologists-summarize-maui-derm-presentations/32839/In this week's DermwireTV, top thought leaders provide a summary of their presentations at Maui Derm; a new analysis examines a link between hidradenitis suppurativa genetics and coronary artery disease risk; and the president of Castle Biosciences joins us for this week's C-Suite Chats fDermwireTV 2024 Year in Review
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-2024-year-in-review/32206/We look back at the top stories of 2024 in the Dermatology and Aesthetics markets. Several new products were approved or launched in atopic dermatitis, rosacea, prurigo nodularis, and hidradenitis suppurativa; new clinical guidelines were made for AD, acne care, and skin cancer; and a new study raisChronic Hand Eczema
https://practicaldermatology.com/series/updates-atopic-dermatitis/chronic-hand-eczema/29146/Dr. Raj Chovatiya, Clinical Associate Professor of Medicine at Rosalind Franklin University Chicago Medical School and Founder and Director of the Center for Medical Dermatology and Immunology Research, talks about chronic hand eczema.Sensus Healthcare: What's Next
https://practicaldermatology.com/topics/skin-cancer-photoprotection/sensus-healthcare-whats-next/19947/Along with other healthcare companies, Sensus faced challenges in 2020 as the COVID-19 pandemic emerged. But CEO Joe Sardano says the company is poised for success in 2021 and beyond. He discusses efforts to optimize physician reimbursement and strategies to expand access for patients.